BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30907306)

  • 1. Targeting Immune Signaling Pathways in Clonal Hematopoiesis.
    Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO
    Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma DP
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of p53 in regulation of hematopoiesis in health and disease.
    Barajas S; Cai W; Liu Y
    Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal Hematopoiesis and therapy related MDS/AML.
    Desai P; Roboz GJ
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):13-23. PubMed ID: 30927970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
    Stankov K; Stankov S; Katanic J
    Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of the inflammasome in myeloid malignancies.
    Chakraborty S; Shapiro LC; de Oliveira S; Rivera-Pena B; Verma A; Shastri A
    Blood Cancer J; 2021 Sep; 11(9):152. PubMed ID: 34521810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
    Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
    Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.
    Ye B; Sheng Y; Zhang M; Hu Y; Huang H
    Cancer Lett; 2022 Jul; 538():215691. PubMed ID: 35469959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation therapy for myeloid malignancies: beyond cytotoxicity.
    Stubbins RJ; Karsan A
    Blood Cancer J; 2021 Dec; 11(12):193. PubMed ID: 34864823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
    Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
    Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate immune signaling in the myelodysplastic syndromes.
    Starczynowski DT; Karsan A
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
    Sperling AS; Gibson CJ; Ebert BL
    Nat Rev Cancer; 2017 Jan; 17(1):5-19. PubMed ID: 27834397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
    Carr RM; Patnaik MM
    Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
    Pedersen-Bjergaard J; Andersen MK; Andersen MT; Christiansen DH
    Leukemia; 2008 Feb; 22(2):240-8. PubMed ID: 18200041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.